Volkmar Müller

Jun 18, 2024 | preprints.org | Volkmar Müller

PreprintArticleVersion 1This version is not peer-reviewedVersion 1: Received: 15 June 2024 / Approved: 18 June 2024 / Online: 18 June 2024 (09:42:58 CEST)Müller, V. Cosmic Expansion – Clues From the Earth. Preprints 2024, 2024061202. https://doi.org/10.20944/preprints202406.1202.v1Müller, V. Cosmic Expansion – Clues From the Earth. Preprints 2024, 2024061202. https://doi.org/10.20944/preprints202406.1202.v1 Export citation file:Bib TeX|RISMDPI and ACS StyleMüller, V.

Jun 3, 2024 | high5oncology.tv | Valentina Guarneri |Diana Lüftner |Alessandra Gennari |Volkmar Müller

Breast cancer early - 100 seconds ENG Breast cancer early - 100 seconds multi language Breast cancer metastatic - 100 seconds ENG Endocrine therapy with Palbociclib + Trastuzumab Chemo-free regimen in HER2+ luminal breast cancer Systemic therapy of HER2+ patients with brain metastases Leptomeningeal metastases in HER2+ mBC Novel ADC-ICI combination therapy HER2+ mBC 1stL T-Dxd Low ER-receptor: endocrine therapy necessary after all? Broaden T-DXD as therapy standard for HER2low and ultra-low...

Dec 5, 2023 | emjreviews.com | Antonio Llombart-Cussac |Virginia Kaklamani |Volkmar Müller

Introduction Over 70% of breast cancers are ER+/HER2-, for which the backbone of treatment is endocrine therapy.1-3 Endocrine therapies for ER+/HER2- advanced breast cancer at 1L include aromatase inhibitors, such as anastrozole, letrozole, and exemestane; selective oestrogen receptor modulators, such as tamoxifen; and SERDs, such as fulvestrant.4 Antonio Llombart-Cussac, Head of Medical Oncology at the Arnau de Vilanova Hospital in Valencia, Spain, emphasised that the addition of CDK4/6...

Feb 23, 2023 | cancertreatmentreviews.com | Volkmar Müller |Rupert Bartsch |Nancy Lin |Filippo Montemurro

Monoclonal antibodyNCT01004172*[54]Leone J.P. Emblem K.E. Weitz M. Gelman R.S. Schneider B.P. Freedman R.A. et al. Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Phase 2, single-arm, open-label trialBevacizumab (monotherapy 15 mg/kg IV on cycle 1 day 1) + carboplatin (IV, AUC = 5, on cycle 1 day 8; HER2– cohort only). Patients with HER2-positive disease also received trastuzumab (8 mg/kg load if indicated; otherwise, 6 mg/kg on cycle 1 day 8).